Driving Progress in Posttraumatic Stress Disorder Biomarkers

Posttraumatic stress disorder (PTSD) is a common, debilitating disorder that affects ∼8% of the U.S. population, with even higher estimates of ∼20%, in U.S. veterans of Afghanistan and Iraq (1). Although psychotherapeutic and pharmacological interventions can significantly reduce PTSD symptoms, there remains considerable room for improvement (2,3). Only two pharmacological thera peutics, sertraline and paroxetine, have been approved by the U.S. Food and Drug Administration (FDA) for PTSD (2). Response to these selective serotonin reuptake inhibitors rarely exceeds 60%, and only 20% to 30% of patients achieve complete remission of symptoms (3).

Source: Biological Psychiatry - October 13, 2019 Category: Psychiatry Authors: Andreas Jeromin, Heather C. Lasseter, Allison C. Provost, Nikolaos P. Daskalakis, Amit Etkin, Philip Gehrman, Lee Lancashire, Brian P. Marx, Regina McGlinchey, Magali Haas Tags: Correspondence Source Type: research